NASDAQ:VACC Vaccitech (VACC) Stock Price, News & Analysis $1.28 +0.05 (+4.07%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$1.25▼$1.3050-Day Range$1.19▼$5.0052-Week Range$1.64▼$5.10Volume75,075 shsAverage Volume244,643 shsMarket Capitalization$49.34 millionP/E RatioN/ADividend YieldN/APrice Target$7.63 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Get Vaccitech alerts: Email Address Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade About Vaccitech Stock (NASDAQ:VACC)Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Read More VACC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VACC Stock News HeadlinesAugust 12, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Barinthus Biotherapeutics Amid Promising Clinical AdvancementsAugust 9, 2024 | markets.businessinsider.comBRNS Stock Earnings: Barinthus Biotherapeutics Misses EPS for Q2 2024September 7, 2024 | Behind the Markets (Ad)⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.July 31, 2024 | uk.finance.yahoo.comHow real are the threats to the US dollar?July 29, 2024 | finance.yahoo.comZoster Vaccine Market to Reach $9.1 Billion by 2033; Increasing Cases of Herpes Zoster Drives the Market's GrowthMay 22, 2024 | markets.businessinsider.comBarinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024May 17, 2024 | markets.businessinsider.comBuy Rating for Barinthus Biotherapeutics Backed by Strong Financials and Promising Clinical TrialsApril 30, 2024 | msn.comWhat is AstraZeneca Vaccine? Know the Recently Discovered Side Effects of the COVID-19 AntibodySeptember 7, 2024 | Behind the Markets (Ad)⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.April 19, 2024 | markets.businessinsider.comBuy Rating on Barinthus Biotherapeutics Backed by Promising Clinical Trials and Strong Valuation ProspectsApril 6, 2024 | msn.comLondon is a bad place to raise money, says life sciences tsar Sir John BellMarch 2, 2024 | seekingalpha.comArbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call TranscriptJanuary 8, 2024 | markets.businessinsider.comPositive Clinical Outlook and Strong Capital Position Justify Buy Rating for Barinthus BiotherapeuticsJanuary 8, 2024 | finanznachrichten.deBarinthus Biotherapeutics: Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate MilestonesJanuary 5, 2024 | finance.yahoo.comBarinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate MilestonesDecember 22, 2023 | markets.businessinsider.comBuy Rating for Barinthus Biotherapeutics: Promising Pipeline and Strategic Partnerships Signal Investment OpportunityDecember 21, 2023 | markets.businessinsider.comBarinthus Biotherapeutics Collaborates With CEPI And University Of Oxford For New MERS VaccineDecember 21, 2023 | finance.yahoo.comNew partnership aims to advance vaccine against MERS coronavirusSee More Headlines Receive VACC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaccitech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VACC CUSIPN/A CIK1828185 Webwww.vaccitech.co.uk Phone44-18-6581-8808FaxN/AEmployees33Year FoundedN/APrice Target and Rating Average Stock Price Target$7.63 High Stock Price Target$12.00 Low Stock Price Target$3.25 Potential Upside/Downside+495.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$5.34 million Net Margins-409.18% Pretax Margin-442.00% Return on Equity-23.41% Return on Assets-20.85% Debt Debt-to-Equity RatioN/A Current Ratio15.26 Quick Ratio15.26 Sales & Book Value Annual Sales$13.42 million Price / Sales3.68 Cash Flow$0.07 per share Price / Cash Flow19.30 Book Value$6.52 per share Price / Book0.20Miscellaneous Outstanding Shares38,547,000Free Float36,234,000Market Cap$49.34 million OptionableNot Optionable Beta-0.40 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. William J. Enright MBA (Age 60)CEO & Director Comp: $916.62kMs. Sarah GilbertCo-FounderMr. Adrian Hill Ph.D.Co-Founder & Scientific AdvisorMs. Gemma Brown (Age 33)CFO & Company Secretary Mr. Chris Ellis (Age 63)Chief Operating Officer Dr. Nadege Pelletier Ph.D. (Age 45)Chief Scientific Officer Mr. Graham Griffiths (Age 44)Chief Business Officer Ms. Elizabeth Eagling-Vose M.B.A.Head of Clinical OperationsBernie McDonaldHead of IPGeoffrey LynnSenior Vice President of Synthetic ImmunotherapiesMore ExecutivesKey CompetitorsPyxis OncologyNASDAQ:PYXSGossamer BioNASDAQ:GOSSOrganigramNASDAQ:OGIContext TherapeuticsNASDAQ:CNTXCybinNYSE:CYBNView All Competitors VACC Stock Analysis - Frequently Asked Questions How have VACC shares performed this year? Vaccitech's stock was trading at $3.69 at the start of the year. Since then, VACC shares have decreased by 65.3% and is now trading at $1.28. View the best growth stocks for 2024 here. How were Vaccitech's earnings last quarter? Vaccitech plc (NASDAQ:VACC) posted its earnings results on Friday, November, 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.25. The business earned $0.02 million during the quarter, compared to the consensus estimate of $1.65 million. Vaccitech had a negative trailing twelve-month return on equity of 23.41% and a negative net margin of 409.18%. When did Vaccitech IPO? Vaccitech (VACC) raised $110 million in an initial public offering on Friday, April 30th 2021. The company issued 6,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, Jefferies, Barclays and William Blair acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager. How do I buy shares of Vaccitech? Shares of VACC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VACC) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccitech plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaccitech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.